![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells is under investigation as an approach to restore productive T cell immunosurveillance in patients with pancreatic ductal adenocarcinoma. Early findings demonstrate safety of this cell-based therapy and the capacity of CAR-expressing T cells to mediate anti-tumor activity as well as induce endogeneous antitumoral immune responses.
Citation: Beatty GL. Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. OncoImmunology 2014; 3:e28327; 10.4161/onci.28327
Disclosure of Potential Conflicts of Interest
G.L.B declares receipt of research funding from Novartis.
Acknowledgments
The author is supported by grants from the National Institutes of Health (K08 CA138907), Department of Defense (W81XWH-12–1-0411), Grant 2013107 from the Doris Duke Charitable Foundation, and the Damon Runyon Cancer Research Foundation for which G.L.B. is the Nadia's Gift Foundation Innovator of the Damon Runyon-Rachleff Innovation Award (DRR-15–12).
